IL6 and rheumatoid arthritis: Notably, tofacitinib also exerts anti-angiogenic effects by decreasing the production of IL-6, VEGF, bFGF, epidermal (EGF), and placental (PlGF) growth factors in RA patients after one year of therapy [48].